Interaction of digitalis-like compounds with P-glycoprotein

Toxicological Sciences

Volumn 131, Issue 2, 2013, Pages 502-511

  Gozalpour, Elnaz ^a   Wittgen, Hanneke G M ^a   van den Heuvel, Jeroen J M W ^a   Greupink, Rick ^a   Russel, Frans G M ^a   Koenderink, Jan B ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Baculovirus; Digitalis like compounds; Mutagenesis; P glycoprotein; Vesicle assay

Indexed keywords

ALANINE; CYMARIN; DIGITALIS LIKE FACTOR; DIGITOXIN; DIGOXIN; HYDROXYL GROUP; ISOLEUCINE; LEUCINE; MULTIDRUG RESISTANCE PROTEIN; PERUVOSIDE; PHENYLALANINE; PROSCILLARIDIN; QUINIDINE DERIVATIVE; STROPHANTHIDIN; THREONINE; VALINE;

ARTICLE; ASSAY; BACULOVIRUS EXPRESSION SYSTEM; CONTROLLED STUDY; DRUG BINDING; MUTANT; SITE DIRECTED MUTAGENESIS; VESICULAR TRANSPORT ASSAY; WESTERN BLOTTING; WILD TYPE;

BLOTTING, WESTERN; CARDIAC GLYCOSIDES; DIGITALIS; HEK293 CELLS; HUMANS; KINETICS; MUTAGENESIS, SITE-DIRECTED; P-GLYCOPROTEIN;

EID: 84873821809     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfs307     Document Type: Article

References (41)

1. Abad-Santos, F., Carcas, A. J., Ibanez, C., and Frias, J. (2000). Digoxin level and clinical manifestations as determinants in the diagnosis of digoxin toxicity. Ther. Drug Monit. 22, 163-168.
2. Aller, S. G., Yu, J., Ward, A., Weng, Y., Chittaboina, S., Zhuo, R., Harrell, P. M., Trinh, Y. T., Zhang, Q., and Urbatsch, I. L., et al. (2009). Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 323, 1718-1722.
3. Belz, G. G., Doering, W., Munkes, R., and Matthews, J. (1983). Interaction between digoxin and calcium antagonists and antiarrhythmic drugs. Clin. Pharmacol. Ther. 33, 410-417.
4. Boyd, R. A., Stern, R. H., Stewart, B. H., Wu, X., Reyner, E. L., Zegarac, E. A., Randinitis, E. J., and Whitfield, L. (2000). Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoproteinmediated secretion. J. Clin. Pharmacol. 40, 91-98.
5. Cavet, M. E., West, M., and Simmons, N. L. (1996). Transport and epithelial secretion of the cardiac glycoside, digoxin, by human intestinal epithelial (Caco-2) cells. Br. J. Pharmacol. 118, 1389-1396.
6. de Lannoy, I. A., and Silverman, M. (1992). The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin. Biochem. Biophys. Res. Commun. 189, 551-557.
7. El-Sheikh, A. A., van den Heuvel, J. J., Krieger, E., Russel, F. G., and Koenderink, J. B. (2008). Functional role of arginine 375 in transmembrane helix 6 of multidrug resistance protein 4 (MRP4/ABCC4). Mol. Pharmacol. 74, 964-971.
8. Englund, G., Hallberg, P., Artursson, P., Michaelsson, K., and Melhus, H. (2004). Association between the number of coadministered P-glycoprotein inhibitors and serum digoxin levels in patients on therapeutic drug monitoring. BMC Med. 2, 8.
9. Hallbook, H., Felth, J., Eriksson, A., Fryknas, M., Bohlin, L., Larsson, R., and Gullbo, J. (2011). Ex vivo activity of cardiac glycosides in acute leukaemia. PLoS ONE 6, e15718.
10. Haynes, K., Hennessy, S., Localio, A. R., Cohen, A., Leonard, C. E., Kimmel, S. E., Feldman, H. I., Strom, B. L., and Metlay, J. P. (2009). Cancer incidence in The Health Improvement Network. Pharmacoepidemiol. Drug Saf. 18, 730-736.
11. Hoffmeyer, S., Burk, O., von Richter, O., Arnold, H. P., Brockmoller, J., Johne, A., Cascorbi, I., Gerloff, T., Roots, I., and Eichelbaum, M., et al. (2000). Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. U.S.A. 97, 3473-3478.
12. Hooiveld, G. J., Heegsma, J., van Montfoort, J. E., Jansen, P. L., Meijer, D. K., and Muller, M. (2002). Stereoselective transport of hydrophilic quaternary drugs by human MDR1 and rat Mdr1b P-glycoproteins. Br. J. Pharmacol. 135, 1685-1694.
13. Johne, A., Kopke, K., Gerloff, T., Mai, I., Rietbrock, S., Meisel, C., Hoffmeyer, S., Kerb, R., Fromm, M. F., and Brinkmann, U., et al. (2002). Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin. Pharmacol. Ther. 72, 584-594.
14. Jutabha, P., Wempe, M. F., Anzai, N., Otomo, J., Kadota, T., and Endou, H. (2010). Xenopus laevis oocytes expressing human P-glycoprotein: Probing trans- and cis-inhibitory effects on [3H]vinblastine and [3H]digoxin efflux. Pharmacol. Res. 61, 76-84.
15. Kurzawski, M., Bartnicka, L., Florczak, M., Gornik, W., and Drozdzik, M. (2007). Impact of ABCB1 (MDR1) gene polymorphism and P-glycoprotein inhibitors on digoxin serum concentration in congestive heart failure patients. Pharmacol. Rep. 59, 107-111.
16. Lee, C. A., Cook, J. A., Reyner, E. L., and Smith, D. A. (2010). P-glycoprotein related drug interactions: Clinical importance and a consideration of disease states. Expert Opin. Drug Metab. Toxicol. 6, 603-619.
17. Loo, T. W., and Clarke, D. M. (2005). Recent progress in understanding the mechanism of P-glycoprotein-mediated drug efflux. J. Membr. Biol. 206, 173-185.
18. Loo, T. W., Bartlett, M. C., and Clarke, D. M. (2006a). Transmembrane segment 1 of human P-glycoprotein contributes to the drug-binding pocket. Biochem. J. 396, 537-545.
19. Loo, T. W., Bartlett, M. C., and Clarke, D. M. (2006b). Transmembrane segment 7 of human P-glycoprotein forms part of the drug-binding pocket. Biochem. J. 399, 351-359.
20. Loo, T. W., Bartlett, M. C., and Clarke, D. M. (2007). Suppressor mutations in the transmembrane segments of P-glycoprotein promote maturation of processing mutants and disrupt a subset of drug-binding sites. J. Biol. Chem. 282, 32043-32052.
21. Loo, T. W., Bartlett, M. C., and Clarke, D. M. (2008). Processing mutations disrupt interactions between the nucleotide binding and transmembrane domains of P-glycoprotein and the cystic fibrosis transmembrane conductance regulator (CFTR). J. Biol. Chem. 283, 28190-28197.
22. Loo, T. W., Bartlett, M. C., and Clarke, D. M. (2009). Identification of residues in the drug translocation pathway of the human multidrug resistance P-glycoprotein by arginine mutagenesis. J. Biol. Chem. 284, 24074-24087.
23. Loo, T. W., and Clarke, D. M. (1996). Inhibition of oxidative cross-linking between engineered cysteine residues at positions 332 in predicted transmembrane segments ™ 6 and 975 in predicted TM12 of human P-glycoprotein by drug substrates. J. Biol. Chem. 271, 27482-27487.
24. Loo, T. W., and Clarke, D. M. (1999a). Determining the structure and mechanism of the human multidrug resistance P-glycoprotein using cysteine-scanning mutagenesis and thiol-modification techniques. Biochim. Biophys. Acta 1461, 315-325.
25. Loo, T. W., and Clarke, D. M. (1999b). Identification of residues in the drugbinding domain of human P-glycoprotein. Analysis of transmembrane segment 11 by cysteine-scanning mutagenesis and inhibition by dibromobimane. J. Biol. Chem. 274, 35388-35392.
26. Loo, T. W., and Clarke, D. M. (2002a). Location of the rhodamine-binding site in the human multidrug resistance P-glycoprotein. J. Biol. Chem. 277, 44332-44338.
27. Loo, T. W., and Clarke, D. M. (2002b). Vanadate trapping of nucleotide at the ATPbinding sites of human multidrug resistance P-glycoprotein exposes different residues to the drug-binding site. Proc. Natl. Acad. Sci. U.S.A. 99, 3511-3516.
28. Lopez-Lazaro, M. (2007). Digitoxin as an anticancer agent with selectivity for cancer cells: Possible mechanisms involved. Expert Opin. Ther. Targets 11, 1043-1053.
29. Lowes, S., Cavet, M. E., and Simmons, N. L. (2003). Evidence for a non-MDR1 component in digoxin secretion by human intestinal Caco-2 epithelial layers. Eur. J. Pharmacol. 458, 49-56.
30. Pauli-Magnus, C., Murdter, T., Godel, A., Mettang, T., Eichelbaum, M., Klotz, U., and Fromm, M. F. (2001). P-glycoprotein-mediated transport of digitoxin, alpha-methyldigoxin and beta-acetyldigoxin. Naunyn Schmiedebergs Arch. Pharmacol. 363, 337-343.
31. Ravna, A. W., Sylte, I., and Sager, G. (2009). Binding site of ABC transporter homology models confirmed by ABCB1 crystal structure. Theor. Biol. Med. Model. 6, 20.
32. Sakaeda, T., Nakamura, T., Horinouchi, M., Kakumoto, M., Ohmoto, N., Sakai, T., Morita, Y., Tamura, T., Aoyama, N., and Hirai, M. (2001). MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm. Res. 18, 1400-1404.
33. Sharom, F. J. (1995). Characterization and functional reconstitution of the multidrug transporter. J. Bioenerg. Biomembr. 27, 15-22.
34. Shoaf, S. E., Ohzone, Y., Ninomiya, S. I., Furukawa, M., Bricmont, P., Kashiyama, E., and Mallikaarjun, S. (2011). In vitro P-glycoprotein interactions and steady-state pharmacokinetic interactions between tolvaptan and digoxin in healthy subjects. J. Clin. Pharmacol. 51, 761-769.
35. Shukla, S., Schwartz, C., Kapoor, K., Kouanda A., and Ambudkar, S. A. (2012). Use of baculovirus BacMam vectors for expression of ABC drug transporters in mammalian cells. Drug Metab. Dispos. 40, 304-312.
36. Tran, T. T., Mittal, A., Aldinger, T., Polli, J. W., Ayrton, A., and Bentz, J. (2005). The elementary mass action rate constants of P-gp transport for a confluent monolayer of MDCKII-hMDR1 cells. Biophys. J. 88, 715-738.
37. Verschraagen, M., Koks, C. H., Schellens, J. H., and Beijnen, J. H. (1999). P-glycoprotein system as a determinant of drug interactions: The case of digoxin-verapamil. Pharmacol. Res. 40, 301-306.
38. Vivo, R. P., Krim, S. R., Inklab, M., Tenner, T., and Hodgson, J. (2008). Digoxin: Current use and approach to toxicity. Am. J. Med. Sci. 336, 423-428.
39. Westphal, K., Weinbrenner, A., Giessmann, T., Stuhr, M., Franke, G., Zschiesche, M., Oertel, R., Terhaag, B., Kroemer, H. K., and Siegmund, W. (2000). Oral bioavailability of digoxin is enhanced by talinolol: Evidence for involvement of intestinal P-glycoprotein. Clin. Pharmacol. Ther. 68, 6-12.
40. Wittgen, H. G., van den Heuvel, J. J., van den Broek, P. H., Dinter-Heidorn, H., Koenderink, J. B., and Russel, F. G. (2011). Cannabinoid type 1 receptor antagonists modulate transport activity of multidrug resistance-associated proteins MRP1, MRP2, MRP3, and MRP4. Drug Metab. Dispos. 39, 1294-1302.
41. Woodland, C., Ito, S., and Koren, G. (1998). A model for the prediction of digoxin-drug interactions at the renal tubular cell level. Ther. Drug Monit. 20, 134-138.